TokenPost·
Bio-Rad Narrows 2026 Operating Margin Target to Upper Half of Range
The company maintained its non-GAAP gross-margin range of 53% to 54% and kept its currency-neutral revenue outlook.
More news
- CoinDeskBitcoin recovers $76,000 level as ETFs shed $430 million after tech rout
- TokenPostWolverine Reports 147,390 Fewer Bitwise XRP ETF Shares in Q3
- TokenPostTenArmorAlert Flags Suspected BSC TENDRIL/USDT Attack With About $309,000 in Losses
- TokenPostSouth Korea's Government Seeks to Delay Crypto Gains Tax Until 2029
- TokenPostCrypto PACs’ Nearly $200 Million Push Failed to Unseat Brown in Ohio
- TokenPostAI-Linked Shares Rally as Micron Rises 8.3% and SanDisk Jumps 10.17%